Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Lurbinectedin has received priority review under the FDA's accelerated approval pathway. Data from a key Phase 2 study of the drug Lurbinectedin demonstrated a clinically meaningful advantage over current standard of care in patients in second-line SCLC therapy.